Stifel Downgrades Crinetics (CRNX) to Hold

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. CSX
7. LRCX
8. MRK
9. LVS
10. SAP

Go back to Stifel Downgrades Crinetics (CRNX) to Hold

Vertex to Acquire Crinetics Pharmaceuticals

July 6, 2026 4:04 PM EDT

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertexs portfolio -

- PALSONIFY®, Crinetics recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake -

- Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has... More